SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis Clinical Trial

Official title:

A Randomized, Double-blind, Placebo-controlled Phase II/III Trial Evaluating the Efficacy and Safety of Sufenidone (SC1011) Tablets in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06125327
• Other study ID #: JYP1011M201
• Status: Recruiting
• Phase: Phase 2/Phase 3
• Start date: June 6, 2023
• Est. completion date: December 31, 2025

Study information

• Verified date: October 2023
• Source: Guangzhou JOYO Pharma Co., Ltd
• Contact: zuojun xu
• Phone: +86 010-69156114
• Email: Xuzj[@]hotmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to evaluate the efficacy and safety of Sufenidone (SC1011) in patients with IPF, and to provide a new safe and effective treatment option for patients with IPF. Participants will complete the study including screening period, treating period, and follow-up period. Investigators will compare the annual rate of decline in FVC to see if it is an optional new drug. The participants have lung function tests at study visits. The results of the lung function tests are compared between the SC1011 groups and the placebo group. The doctors also regularly check the general health of the participants.

Description:

This is a randomized, double-blind, placebo-controlled study using a phase II/III adaptive seamless design. The study isdivided into three treatment groups: two active treatment groups and one placebo group. An interim analysis will be performed after the completion of 26 weeks of treatment in 75 patients. According to the safety and efficacy results analyzed, the appropriate active dose will be selected. Subjects will be divided into 3 treatment groups in a ratio of 1:1:1; After the interim analysis, if the DMC selected a treatment dose, all new recruits would be randomly assigned to the treatment and placebo groups in a 2:1 ratio. Subjects who were enrolled before the interim analysis will be adjusted to continue treatment at the selected dose up to 52 weeks. This study includes screening period, treatment period and follow-up period. During the screening period, the subjects' lung imaging examinations performed at different centers required a central imaging diagnosis. The first dose after randomization is D1, and the treatment period for each subject is 52 weeks. All subjects will have a 4-week safety follow-up period after the end of treatment. Subjects who do not complete 52 weeks of treatment will also have a 4-week safety follow-up after the final dosing date.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 210
• Est. completion date: December 31, 2025
• Est. primary completion date: December 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 80 Years

Eligibility

Inclusion Criteria:

• Ability to understand and sign written informed consent.
• The diagnosis time of IPF before enrollment was less than 5 years.
• Combination of High Resolution Computerized Tomography (HRCT) pattern, and if available surgical lung biopsy pattern, as assessed by central reviewers, are consistent with diagnosis of IPF.
• Dlco (corrected for Hb): 30%-90% predicted of normal.
• FVC>= 50% predicted of normal.

Exclusion Criteria:

• Forced expiratory volume in one second (FEV1)/FVC ratio <0.7 after administration of bronchodilator at Screening
• Expected to receive a lung transplant within 1 year from randomization or, for patients at sites in the United States, on a lung transplant waiting list at randomization.
• Known explanation for interstitial lung disease
• History of asthma or chronic obstructive pulmonary disease
• Active infection
• Ongoing IPF treatments including investigational therapy, immunosuppressants, and cytokine modulating agents
• History of unstable or deteriorating cardiac or pulmonary disease (other than IPF) within the previous 6 months

Related Conditions & MeSH terms

• Fibrosis
• Idiopathic Pulmonary Fibrosis
• Pulmonary Fibrosis

Intervention

Drug:
• SC1011
Patients receive the dose of SC1011 tablets orally twice daily (b.i.d) for 52 weeks.
• Placebo comparator
Patients receive the dose of placebo orally twice daily (b.i.d) for 52 weeks.

Locations

Country	Name	City	State
China	Peking Union Medical College Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Guangzhou JOYO Pharma Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks	Forced vital capacity (FVC) is the total amount of air exhaled during the lung function test. For this endpoint reported means represent the adjusted rate.	Baseline and 52 weeks
Secondary	Change From Baseline in Saint-George's Respiratory Questionnaire (SGRQ) Total Score at 52 Weeks	SGRQ is a health-related quality of life questionnaire divided into 3 components : symptoms, activity and impact.The total score (summed weights) can range from 0 to 100 with a lower score denoting a better health status. Means provided are the adjusted means based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52)	Baseline and 52 weeks
Secondary	Time to First Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbation.	Due to rare events, the median of time to event is not calculable, thus the percentages of patients with (IPF) exacerbation are reported and represented as a key secondary endpoint.	Week 52